Shares of Onyx Pharmaceuticals Inc. jumped 51.3 percent Monday after it rejected over the weekend an unsolicited $10 billion bid from Amgen Inc. and said it would seek other potential offers. Read More
What a difference a quarter makes. Three months ago, I was lamenting about how venture capital investing was off to a slow start in 2013. After tallying the totals for the second quarter, it looks like the first quarter was more of a pause than a trend. Read More
LONDON – The UK government has given the go-ahead to mitochondrial replacement in in vitro fertilization, a technology that would result in children being born with DNA from three people. Read More
Investors were less than impressed with the results from Insmed Inc.'s Phase III trial for Arikace, its liposomal amikacin for inhalation. The Monmouth Junction, N.J.-based company saw its shares (NASDAQ:INSM) plummet 18.7 percent, or $2.24, to close at $9.72 Monday. Read More
• Tengion Inc., of Winston-Salem, N.C., closed transactions totaling $33.6 million to fund its two lead clinical programs, the Neo-Kidney Augment and the Neo-Urinary Conduit. Read More
• Bayer HealthCare Pharmaceuticals Inc., of Berkeley, Calif., and Onyx Pharmaceuticals Inc., of South San Francisco, submitted a supplemental new drug application to the FDA and an application for marketing authorization to the European Medicines Agency for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer. Read More
• Noven Pharmaceuticals Inc., of Miami, said the FDA approved Brisdelle low-dose paroxetine capsules, 7.5 mg/day, for the treatment of moderate to severe vasomotor symptoms associated with menopause, the first nonhormonal treatment for hot flashes. Read More
• Halozyme Therapeutics Inc., of San Diego, reported interim results from a proof-of-concept Phase I/II trial evaluating the activity and local tolerability of HTI-501, an investigational biologic, for use in aesthetic dermatology. Read More
• Bristol-Myers Squibb Co., of Princeton, N.J., and Pfizer Inc., of New York, reported results of the six-month Phase III AMPLIFY trial of 5,395 patients with acute venous thromboembolism (VTE), which includes symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE). Read More
TAIPEI, Taiwan – Drug reformulation specialist Taiwan Liposome Co. (TLC), of Taipei, Taiwan, said it granted Sciclone Pharmaceuticals Inc., of Foster City, Calif., exclusive rights to distribute Proflow, its treatment for peripheral arterial disease (PAD), in China, Macau and Hong Kong. Read More
